Carregant...
Two decades with omalizumab: what we still have to learn
From its availability for clinical use nearly two decades ago for severe asthma, omalizumab has gained strong evidence of efficacy and safety in the treatment of severe asthma not controlled by standard-of-care therapy. It has been acknowledged by Global Initiative on Asthma guidelines as add-on the...
Guardat en:
| Publicat a: | Biologics |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6208531/ https://ncbi.nlm.nih.gov/pubmed/30464389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S180846 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|